中国临床医学2024，Vol.31Issue(5)：832-837,6.DOI:10.12025/j.issn.1008-6358.2024.20240598
放射性核素标记成纤维细胞激活蛋白抑制剂在肝癌诊疗中的临床应用进展
Research progress for the clinical application of radionuclide labeling fibroblast activation protein inhibitor in the diagnosis and treatment of liver cancer
摘要
Abstract
Liver cancer has high morbidity and mortality worldwide.Traditional morphological imaging can offer crucial anatomical information for the diagnosis and treatment of liver cancer,and when combined with the functional data shown by PET imaging,the diagnostic accuracy of tumors can be further improved and assisted in treatment selection.Fibroblast activation protein(FAP),a signature protein of cancer-associated fibroblasts,is highly expressed in a variety of malignant tumors of epithelial origin and is an important target for tumor diagnosis and treatment.Compared with routinely applied 18F-fluorodeoxyglucose(FDG)PET imaging,FAP inhibitor(FAPI)PET imaging has the advantages of high image contrast and independence from blood glucose.In recent years,a variety of radiopharmaceuticals targeting FAP have been continuously expanded in the diagnosis,staging and targeted therapy of different liver cancer types,and the progress of their related applications is reviewed in this paper.关键词
肝癌/成纤维细胞激活蛋白抑制剂/18F-氟代脱氧葡萄糖/正电子发射断层显像术/体层摄影术/X线计算机Key words
liver cancer/fibroblast activation protein inhibitor/18F-fluorodeoxyglucose/positron-emission tomography/tomography/X-ray computed分类
医药卫生引用本文复制引用
何依波,石洪成..放射性核素标记成纤维细胞激活蛋白抑制剂在肝癌诊疗中的临床应用进展[J].中国临床医学,2024,31(5):832-837,6.基金项目
国家临床重点专科建设项目(YWP2022-007).Supported by National Clinical Key Specialty Construction Program of China(YWP2022-007). （YWP2022-007）
